Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022)
Nexalin Technology (NXL) recorded quarterly Long-Term Deferred Tax of $3.3 million in Q4 2022, up 12.91% quarter-over-quarter from $3.0 million in Q4 2021, and up 12.91% on a YoY basis from $3.0 million in Q4 2021.
Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
Nexalin Technology's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $3.3 million for Q4 2022.
- In Q4 2022, Long-Term Deferred Tax rose 12.91% year-over-year to $3.3 million; the TTM figure through Dec 2022 stood at $3.3 million (up 12.91% YoY), while the FY2022 annual figure was $3.3 million, up 12.91% from the prior year.
- Long-Term Deferred Tax was $3.3 million for Q4 2022 at Nexalin Technology, up from $3.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $3.3 million in Q4 2022 to a low of $3.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 2.96 Mn |